Perimenopausal use of reproductive hormones: Effects on breast and endometrial cancer

Obstetrics and Gynecology Clinics of North America

Volumn 29, Issue 3, 2002, Pages 511-525

  Collins, John A ^a,d   Schlesselman, James J ^b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d RR 1 Mader's Cove ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

ALCOHOL CONSUMPTION; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; CONTRACEPTION; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FAMILY HISTORY; FEMALE; GENETIC PREDISPOSITION; HORMONE SUBSTITUTION; HUMAN; MENARCHE; MENOPAUSE; META ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SOCIOECONOMICS; UNITED STATES;

BREAST NEOPLASMS; CLIMACTERIC; CONTRACEPTIVES, ORAL, HORMONAL; ENDOMETRIAL NEOPLASMS; FEMALE; GONADAL STEROID HORMONES; HORMONE REPLACEMENT THERAPY; HUMANS; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 0036739924     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8545(02)00013-X     Document Type: Review

References (60)

1. Rosner B, Colditz GA, Willett WC. Reproductive risk factors in a prospective study of breast cancer. Am J Epidemiol 1994;139:819-35.
2. Beral V, Hermon C, Kay C, et al. Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46,000 women from Royal College of General Practitioners' oral contraception study. BMJ 1999;318:96-100.
3. Beresford SAA, Weiss NS, Voigt LF, et al. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997; 349:458-61.
4. Velentgas P, Daling JR. Risk factors for breast cancer in younger women. Monogr Natl Cancer Inst 1994;16:15-22.
5. Kelsey JL, Whittemore AS. Epidemiology and primary prevention of cancers of the breast, endometrium, and ovary: a brief overview. Ann Epidemiol 1994;4:89-95.
6. Sulak PJ. Endometrial cancer and hormone replacement therapy. Endocrinol Metab Clin North Am 1997;26:399-411.
7. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347: 1713-27.
8. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.
9. Collins JA, Schlesselman JJ. Hormone replacement therapy and endometrial cancer. In: Lobo RA, editor. Treatment of the postmenopausal woman. 2nd edition. Philadelphia: Lippincott Williams and Wilkins; 1999. p. 503-12.
10. Schlesselman JJ. Risk of endometrial cancer in relation to use of combined oral contraceptives: a practitioner's guide to meta-analysis. Hum Reprod 1997;12:1851-63.
11. Wysowski DK, Golden L, Burke L. Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstet Gynecol 1995;85:6-10.
12. King R, Whitehead M, Campbell S, et al. Effect of estrogen and progestin treatments on endometria from postmenopausal women. Cancer Res 1979;39:1094-101.
13. Kurman RJ, Zaino RJ, Norris HJ. Endometrial carcinoma. In Kurman RJ, editor. Blaustein's pathology of the female genital tract. 4th edition. New York: Springer-Verlag; 1994. p. 439-86.
14. Whitehead M, Townsend P, Pryse-Davies J, et al. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 1981;305: 1599-605.
15. Henderson BE, Ross RK, Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 1988;48:246-51.
16. Wu L, Einstein M, Geissler WM, et al. Expression cloning and characterization of human 17betahydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20alphahydroxysteroid dehydrogenase activity. J Biol Chem 1993;268:12964-9.
17. PEPI Trial Writing Group. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. JAMA 1996;275:370-5.
18. Speroff L, Rowan J, Symons J, et al. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART Study): a randomized controlled study. JAMA 1996;276:1397-403.
19. Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994;170:1213-23.
20. Feuer EJ, Wun L-M. DEVCAN: probability of developing or dying of cancer software, version 4.0. Washington DC: National Cancer Institute; 1999.
21. Schlesselman JJ, Collins JA. The influence of steroids on gynecologic cancers. In: Fraser IS, Jansen RPS, Lobo RA, et al, editors. Estrogens and progestogens in clinical practice. London: Churchill Livingston; 1999. p. 831-64.
22. American Cancer Society and Surveillance Research. Cancer facts and figures. Atlanta: American Cancer Society; 2000.
23. Ries LAG, Eisner MP, Kosary CL, et al. Corpus and uterus, NOS cancer (invasive). In: Ries LAG, Eisner MP, Kosary CL, et al, editors. SEER cancer statistics review 1973-1997. Bethesda, MD: National Cancer Institute; 2000. p. 1-11.
24. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. Combination oral contraceptive use and the risk of endometrial cancer. JAMA 1987;257:796-800.
25. World Health Organization. Study of neoplasia and steroid contraceptives. Int J Epidemiol 1988; 17:263-9.
26. Henderson BE, Casagrande JT, Pike MC, et al. The epidemiology of endometrial cancer in young women. Br J Cancer 1983;47:749-56.
27. Voigt LF, Deng Q, Weiss NS. Recency, duration and progestin content of oral contraceptives in relation to the incidence of endometrial cancer (Washington, USA). Cancer Causes Control 1994;5:227-33.
28. Horwitz R, Feinstein AR. Alternative analytic methods for case-control studies of estrogens and endometrial cancer. N Engl J Med 1978;299:1089-94.
29. Hulka B, Fowler W, Kaufman D, et al. Estrogen and endometrial cancer: cases and two control groups from North Carolina. Am J Obstet Gynecol 1980;137:92-101.
30. Stavraky K, Collins JA, Donner A, et al. A comparison of estrogen use by women with endometrial cancer, gynecologic disorders, and other illnesses. Am J Obstet Gynecol 1981; 141:547-55.
31. Antunes C, Stolley P, Rosenshein N, et al. Endometrial cancer and estrogen use: report of a large case-control study. N Engl J Med 1979;300:9-13.
32. Buring JE, Bain CJ, Ehrmann RL. Conjugated estrogen use and risk of endometrial cancer. Am J Epidemiol 1986;124:434-41.
33. Jelovsek F, Hammond C, Woodard B, et al. Risk of exogenous estrogen therapy and endometrial cancer. Am J Obstet Gynecol 1980;137:85-91.
34. Mack TM, Pike MC, Henderson BE, et al. Estrogens and endometrial cancer in a retirement community. N Engl J Med 1976;294:1262-7.
35. McDonald TW, Annegers JF, O'Fallon WM, et al. Exogenous estrogen and endometrial carcinoma: case-control and incidence study. Am J Obstet Gynecol 1977;127:572-9.
36. Collins JA, Allen L, Donner A, et al. Oestrogen use and survival in endometrial cancer. Lancet 1980;2:961-3.
37. Schwartzbaum JA, Hulka BS, Fowler WC, et al. The influence of exogenous estrogen use on survival after diagnosis of endometrial cancer. Am J Epidemiol 1987;126:851-60.
38. Hill DA, Weiss NS, Beresford SA, et al. Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol 2000;183:1456-61.
39. Jick SS. Combined estrogen and progesterone use and endometrial cancer. Epidemiology 1993;4:384.
40. Persson I, Adami H-O, Bergkvist L, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 1989;298:147-51.
41. Pike MC, Peters RK, Cozen W, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997;89:1110-6.
42. Voigt LF, Weiss NS, Chu J, et al. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991;338:274-7.
43. Weiderpass E, Adami H-O, Baron J, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131-7.
44. Varma T. Effect of long-term therapy with estrogen and progesterone on the endometrium of post-menopausal women. Acta Obstet Gynecol Scand 1985;64:41-6.
45. Whitehead M. Prevention of endometrial abnormalities. Acta Obstet Gynecol Scand Suppl 1986;134:81-91.
46. El-Ashry D, Lippman ME. Molecular biology of breast carcinoma. World J Surg 1994;18:12-20.
47. Clemon M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-85.
48. Anderson TJ, Battersby S, King RJB, et al. Oral contraceptive use influences resting breast proliferation. Hum Pathol 1989;20:1139-44.
49. Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998;69:963-9.
50. Hofseth LJ, Raafat AM, Osuch JR, et al. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84:4559-65.
51. Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1973-1998. Bethesda, MD: National Cancer Institute; 2001.
52. Kelsey JL, Gammon MD, John EM: Reproductive factors and breast cancer. Epidemiol Rev 1993;15:36-47.
53. Ries LAG, Eisner MP, Kosary CL, et al. Breast cancer (invasive). In: Ries LAG, Eisner MP, Kosary CL, et al, editors. SEER cancer statistics review 1973-1997. Bethesda, MD: National Cancer Institute; 2000.p. 1-22.
54. Smith-Warner SA, Spiegelman D, Yaun S-S, et al. Alcohol and breast cancer in women. JAMA 1998;279:535-40.
55. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: further results. Contraception 1996;54:1S-106S.
56. Grabrick DM, Hartmann LC, Cerhan JR, et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA 2000;284:1791-8.
57. Magnusson C, Baron JA, Correia N, et al. Breast cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 1999;81:339-44.
58. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-91.
59. Ross RK, Paganini-Hill A, Wan PC, et al. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-32.
60. Sellers TA, Mink PJ, Cerhan JR, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history for breast cancer. Ann Intern Med 1997;127:973-80.